Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Cubist CEO Bonney hands over reins as new buyout rumors circulate

After 11 years at the helm of Cubist Pharmaceuticals, CEO Michael Bonney is stepping down and handing the reins to COO and President Robert Perez.

Incyte taps David Gryska to be its new CFO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Novartis to shed three division heads in midst of Glaxo, Lilly deal prep

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

VC giant NEA recruits biotech vet Carol Gallagher to join its ranks of dealmakers

After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.

UPDATED: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door

There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.

Novartis, GSK shake up executive ranks as overhaul continues

Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.

GE promotes biz dev exec to head healthcare

GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.

Jason Rhodes joins Atlas Venture investing team

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Valeant adds activist shareholder Ubben to board as Allergan takeover bid heats up

In yet another sign that it's not about to abandon its hostile bid to buy Allergan, Valeant has named activist investor Jeffrey Ubben to its board. Ubben is chief executive officer of ValueAct Capital Management, Valeant's second-largest shareholder and a new supporter of the Allergan deal.